A cyberattack has led to a tech outage affecting thousands of patients and employees at Kettering Health facilities in the area. Kettering Health confirmed the attack ...

The market’s positive reaction to OraSure’s stock today reflects investor confidence in the company’s ongoing relationship with 23andMe under Regeneron’s ownership. The continuation of this ...

Regeneron's win at action means the bankrupt firm's popular DNA-testing service can continue — along with a privacy policy allowing customers to have their data deleted.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Regeneron said it will comply with 23andMe's privacy policies and applicable laws with respect to the use of customer data ...

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 5.25% to $598.76 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...

Reported EPS is $8.22 EPS, expectations were $8.62. Operator: Welcome to the Regeneron Pharmaceuticals ... With physician and patient awareness building and strong reimbursement established ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.